A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia

Francis J. Giles*, Jorge E. Cortes, Hagop M. Kantarjian, Susan M. O'Brien, Elihu Estey, Miloslav Beran

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

14 Scopus citations

Fingerprint Dive into the research topics of 'A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia'. Together they form a unique fingerprint.

Medicine & Life Sciences